STAT March 18, 2024
Jason Mast

The Food and Drug Administration on Monday approved a gene therapy for metachromatic leukodystrophy, a devastating genetic disorder that eats away at affected children’s neurons.

The medicine, marketed as Lenmeldy, is the first treatment for MLD, which is otherwise fatal. Lenmeldy has to be given before symptoms appear or, in some cases, after the first signs of disease, so it won’t be helpful for many patients...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
FDA Update for Week of April 22, 2024: Second Gene Therapy for Hemophilia B
11 drugs now in shortage
Pfizer scores FDA nod for hemophilia B gene therapy, will charge $3.5M per dose
FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
FDA Launches ‘Home as a Health Care Hub’ Initiative With Equity Focus

Share This Article